<rss version="2.0"><channel><title>Yahoo! Finance: PLI.TO News</title><copyright>Copyright (c) 2017 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=pli.to</link><description>Latest Financial News for PROMETIC LIFE SCIENCES INC.</description><language>en-US</language><lastBuildDate>Wed, 18 Jan 2017 12:15:00 GMT</lastBuildDate><image><url>http://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif</url><title>Yahoo! Finance: PLI.TO News</title><link>http://finance.yahoo.com/q/h?s=pli.to</link><width>144</width><height>45</height></image><item><title>European Commission grants orphan drug designation to ProMetic's PBI-4050 drug for the treatment of Alstr&#246;m Syndrome</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/european-commission-grants-orphan-drug-121500454.html</link><description>[PR Newswire] - LAVAL, QC, Jan. 18, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF), ("ProMetic" or the "Corporation") announced today that its orally active lead drug candidate, PBI-4050, has been granted an orphan drug designation status for the treatment of Alstr&#246;m Syndrome ("AS") by the European Commission. The European Medicines Agency ("EMA") determined that the intention to treat AS with PBI-4050 was justified based on the preliminary clinical data generated in AS patients showing an improvement in liver fibrosis. ProMetic is currently investigating the effects of PBI-4050 on multiple organs in AS patients in an ongoing open label Phase 2 clinical study in the UK. "The positive results in patients with AS nicely complement those already observed in our other trials in idiopathic pulmonary fibrosis and in metabolic syndrome and type 2 diabetes" commented Dr. John Moran, ProMetic's Chief Medical Officer.</description><guid isPermaLink="false">yahoo_finance/1751496410</guid><pubDate>Wed, 18 Jan 2017 12:15:00 GMT</pubDate></item><item><title>ProMetic Life Sciences, Inc. &#8211; Value Analysis (TORONTO:PLI) : January 12, 2017</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=13h1dmqlp/*http://www.capitalcube.com/blog/index.php/prometic-life-sciences-inc-value-analysis-torontopli-january-12-2017/</link><description /><guid isPermaLink="false">yahoo_finance/3058154824</guid><pubDate>Thu, 12 Jan 2017 15:05:13 GMT</pubDate></item><item><title>ETFs with exposure to ProMetic Life Sciences, Inc. : January 11, 2017</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=13d9u2skc/*http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-prometic-life-sciences-inc-january-11-2017/</link><description /><guid isPermaLink="false">yahoo_finance/813707539</guid><pubDate>Wed, 11 Jan 2017 18:10:58 GMT</pubDate></item><item><title>ProMetic Life Sciences, Inc. breached its 50 day moving average in a Bullish Manner : PLI-CA : January 11, 2017</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=14lmnenah/*http://www.capitalcube.com/blog/index.php/prometic-life-sciences-inc-breached-its-50-day-moving-average-in-a-bullish-manner-pli-ca-january-11-2017/</link><description /><guid isPermaLink="false">yahoo_finance/1005094825</guid><pubDate>Wed, 11 Jan 2017 13:15:52 GMT</pubDate></item><item><title>PROMETIC REACQUIRES PLASMINOGEN RIGHTS FROM HEMATECH</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128bpnk4d/*http://www.publicnow.com/view/E528264C741E9E899DB639CEB878E74FACB9ED08</link><description>[at noodls] - Regains 100% ownership of profits from future sales of plasminogen for congenital deficiency Hematech continues to hold Taiwanese rights to PPPS&#8482; as CMO supplier to ProMetic LAVAL, QUEBEC, CANADA, - January ...</description><guid isPermaLink="false">yahoo_finance/3226595884</guid><pubDate>Thu, 05 Jan 2017 11:44:10 GMT</pubDate></item><item><title>ProMetic reacquires plasminogen rights from Hematech</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-reacquires-plasminogen-rights-hematech-113000941.html</link><description>[CNW Group] - ProMetic reacquires plasminogen rights from Hematech</description><guid isPermaLink="false">yahoo_finance/4171651808</guid><pubDate>Thu, 05 Jan 2017 11:30:00 GMT</pubDate></item><item><title>ETFs with exposure to ProMetic Life Sciences, Inc. : December 27, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=13eg1f1v8/*http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-prometic-life-sciences-inc-december-27-2016/</link><description /><guid isPermaLink="false">yahoo_finance/336493335</guid><pubDate>Tue, 27 Dec 2016 18:40:03 GMT</pubDate></item><item><title>PROMETIC INITIATES ROLLING SUBMISSION OF ITS BIOLOGICS LICENSE APPLICATION (&#8220;BLA&#8221;) FOR PLASMINOGEN WITH U.S. FDA</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1288q90vf/*http://www.publicnow.com/view/4A4A43B5DAEB1CFC7D6938B39F5AD8CEFE8A4CBC</link><description>[at noodls] - LAVAL, QUEBEC, CANADA, - December 19, 2016 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ('ProMetic' or the 'Corporation') announced today that it has initiated the rolling submission of its ...</description><guid isPermaLink="false">yahoo_finance/4084333512</guid><pubDate>Mon, 19 Dec 2016 11:51:16 GMT</pubDate></item><item><title>ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-initiates-rolling-submission-biologics-113000296.html</link><description>[CNW Group] - ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA</description><guid isPermaLink="false">yahoo_finance/1724808552</guid><pubDate>Mon, 19 Dec 2016 11:30:00 GMT</pubDate></item><item><title>ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-initiates-rolling-submission-biologics-113000990.html</link><description>[PR Newswire] - LAVAL, QC, Dec. 19, 2016 /PRNewswire/ - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF) ("ProMetic" or the "Corporation") announced today that it has initiated the rolling submission of its Biologics License Application ("BLA") for plasminogen with the U.S. FDA for treatment of patients with plasminogen congenital deficiency.</description><guid isPermaLink="false">yahoo_finance/1145249947</guid><pubDate>Mon, 19 Dec 2016 11:30:00 GMT</pubDate></item><item><title>PROMETIC COMMENTS ON UNUSUAL TRADING ACTIVITY</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128d0bc8i/*http://www.publicnow.com/view/4EB9BB5E7070767E1A80ECF83E6108971F53FF16</link><description>[at noodls] - LAVAL, QUEBEC, CANADA, - December 16, 2016 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ('ProMetic' or the 'Corporation') responded today at the request of the Investment Industry Regulatory ...</description><guid isPermaLink="false">yahoo_finance/2029852754</guid><pubDate>Fri, 16 Dec 2016 20:50:13 GMT</pubDate></item><item><title>ProMetic comments on unusual trading activity</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-comments-unusual-trading-activity-201100325.html</link><description>[CNW Group] - ProMetic comments on unusual trading activity</description><guid isPermaLink="false">yahoo_finance/1351752561</guid><pubDate>Fri, 16 Dec 2016 20:11:00 GMT</pubDate></item><item><title>ETFs with exposure to ProMetic Life Sciences, Inc. : December 16, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=13euief5c/*http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-prometic-life-sciences-inc-december-16-2016/</link><description /><guid isPermaLink="false">yahoo_finance/2270989633</guid><pubDate>Fri, 16 Dec 2016 17:08:49 GMT</pubDate></item><item><title>ProMetic responds to false market data report regarding insider selling</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-responds-false-market-data-140000447.html</link><description>[PR Newswire] - LAVAL, QC, Dec. 9, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF), ("ProMetic" or the "Corporation") responded today to a false market data report listing amongst others, Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic, as a net seller of 8.85 million shares of ProMetic. While the Corporation does not generally comment publicly on market speculation or rumours, the Corporation believed it was prudent to advise investors that the report is false and that the Corporation's CEO has not sold 8.85 million shares of the Corporation. The Corporation does not anticipate issuing any further public statement regarding any rumours or speculation in the marketplace unless required by applicable laws.</description><guid isPermaLink="false">yahoo_finance/442026793</guid><pubDate>Fri, 09 Dec 2016 14:00:00 GMT</pubDate></item><item><title>ProMetic responds to false market data report regarding insider selling</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-responds-false-market-data-140000125.html</link><description>[CNW Group] - ProMetic responds to false market data report regarding insider selling</description><guid isPermaLink="false">yahoo_finance/948428438</guid><pubDate>Fri, 09 Dec 2016 14:00:00 GMT</pubDate></item><item><title>Research Reports Initiated on Healthcare Stocks Cardiome Pharma, Resverlogix, IntelliPharmaCeutics International, and ProMetic Life Sciences</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://news.investornetwork.com/2016/12/06/research-reports-initiated-on-healthcare-stocks-cardiome-pharma-resverlogix-intellipharmaceutics-international-and-prometic-life-sciences/?1=1&amp;1481030382</link><description /><guid isPermaLink="false">yahoo_finance/3797402602</guid><pubDate>Tue, 06 Dec 2016 13:19:42 GMT</pubDate></item><item><title>ETFs with exposure to ProMetic Life Sciences, Inc. : December 5, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=13d2su7h7/*http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-prometic-life-sciences-inc-december-5-2016/</link><description /><guid isPermaLink="false">yahoo_finance/4008571159</guid><pubDate>Mon, 05 Dec 2016 17:30:46 GMT</pubDate></item><item><title>ETFs with exposure to ProMetic Life Sciences, Inc. : November 23, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=13ggf8n4g/*http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-prometic-life-sciences-inc-november-23-2016-2/</link><description /><guid isPermaLink="false">yahoo_finance/3122598984</guid><pubDate>Wed, 23 Nov 2016 18:22:57 GMT</pubDate></item><item><title>ProMetic Life Sciences, Inc. :PLI-CA: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=148uvvtvh/*http://www.capitalcube.com/blog/index.php/prometic-life-sciences-inc-pli-ca-earnings-analysis-q3-2016-by-the-numbers-november-21-2016/</link><description /><guid isPermaLink="false">yahoo_finance/57346322</guid><pubDate>Mon, 21 Nov 2016 15:07:40 GMT</pubDate></item><item><title>ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-presents-pbi-4050s-positive-173600428.html</link><description>[CNW Group] - ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting</description><guid isPermaLink="false">yahoo_finance/3743935579</guid><pubDate>Fri, 18 Nov 2016 17:36:00 GMT</pubDate></item><item><title>ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-presents-pbi-4050s-positive-173600679.html</link><description>[PR Newswire] - LAVAL, QC, Nov. 18, 2016 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (" ProMetic " or the " Corporation ") today announced that it is presenting new data at ...</description><guid isPermaLink="false">yahoo_finance/3407641039</guid><pubDate>Fri, 18 Nov 2016 17:36:00 GMT</pubDate></item><item><title>ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometics-pbi-4050-demonstrates-early-113000430.html</link><description>[PR Newswire] - LAVAL, QC, Nov. 17, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (PLI.TO) (PFSCF) ("ProMetic" or the "Corporation") announced today positive interim results from its Open Label Phase 2 clinical trial in patients suffering from idiopathic pulmonary fibrosis ("IPF"). In addition to demonstrating that PBI-4050 is safe and well tolerated in patients suffering from IPF, the objective of this study was to provide early evidence of clinical benefits of PBI-4050 treatment whether used alone or in addition to either nintedanib or pirfenidone. Forty patients are enrolled in the study in 6 sites across Canada.</description><guid isPermaLink="false">yahoo_finance/843890455</guid><pubDate>Thu, 17 Nov 2016 11:30:00 GMT</pubDate></item><item><title>ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometics-pbi-4050-demonstrates-early-113000864.html</link><description>[CNW Group] - ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial</description><guid isPermaLink="false">yahoo_finance/3141590278</guid><pubDate>Thu, 17 Nov 2016 11:30:00 GMT</pubDate></item><item><title>PROMETIC RECEIVES CLEARANCE FROM HEALTH CANADA TO PROCEED WITH ITS PBI-4050 PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL IN PATIENTS WITH METABOLIC SYNDROME AND TYPE 2 DIABETES</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283elchg/*http://www.publicnow.com/view/DA46B633E730F9B2EB72941A043B13CD4350DCBB</link><description>[at noodls] - LAVAL, QUEBEC, CANADA - November 16, 2016 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ('ProMetic' or the 'Corporation') today reported that it has received clearance by Health Canada to commence ...</description><guid isPermaLink="false">yahoo_finance/3015583207</guid><pubDate>Wed, 16 Nov 2016 11:48:07 GMT</pubDate></item><item><title>ProMetic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial in patients with metabolic syndrome and type 2 diabetes</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-receives-clearance-health-canada-113000431.html</link><description>[CNW Group] - ProMetic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial in patients with metabolic syndrome and type 2 diabetes</description><guid isPermaLink="false">yahoo_finance/2699856493</guid><pubDate>Wed, 16 Nov 2016 11:30:00 GMT</pubDate></item><item><title>ProMetic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial in patients with metabolic syndrome and type 2 diabetes</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/prometic-receives-clearance-health-canada-113000425.html</link><description>[PR Newswire] - The objectives of this 12 week randomized, double-blind, placebo-controlled, multi-center, 4 arm with 67 patients per arm (1 placebo, 3 escalating doses) phase 2 clinical trial includes the evaluation of the effects of PBI-4050 on metabolic syndrome parameters and on pro-inflammatory/fibrotic and diabetic biomarkers in the blood and urine. The phase 2 clinical trial is expected to commence in Q4 2016.</description><guid isPermaLink="false">yahoo_finance/2011391352</guid><pubDate>Wed, 16 Nov 2016 11:30:00 GMT</pubDate></item><item><title>PROMETIC REPORTS THIRD QUARTER 2016 HIGHLIGHTS AND FINANCIAL RESULTS</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128ki1kst/*http://www.publicnow.com/view/3EE93CEDD437DB27456F4372E0BF7FC8605081E4</link><description>[at noodls] - Acquisition of Telesta Therapeutics adds $37.4 million in cash and short-term investments to $39.0 million balance reported at end of Q3 Investment in commercial &amp; manufacturing infrastructure ahead of ...</description><guid isPermaLink="false">yahoo_finance/20378642</guid><pubDate>Tue, 15 Nov 2016 02:17:05 GMT</pubDate></item><item><title>PROMETIC&#8217;S PBI-4050 SHOWN TO REDUCE PULMONARY HYPERTENSION AND LUNG REMODELING AND TO IMPROVE RIGHT VENTRICULAR FUNCTION IN HEART FAILURE WITH REDUCED EJECTION FRACTION (&#8220;HFrEF&#8221;)</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1288qa86a/*http://www.publicnow.com/view/2DF584EB5A8EB19E03C0D530133964FC9EAAFB34</link><description>[at noodls] - Over 5 million Americans suffer from heart failure, the majority having HFrEF The presence of pulmonary hypertension ('PH') with HFrEF significantly increases mortality rate No approved treatment exists ...</description><guid isPermaLink="false">yahoo_finance/2246500349</guid><pubDate>Mon, 14 Nov 2016 11:47:08 GMT</pubDate></item><item><title>Q3 2016 FINANCIAL RESULTS CONFERENCE CALL &amp; WEBCAST</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128e2q0up/*http://www.publicnow.com/view/32DA42C00A767407B9D7A0F81F69E9958C9DA179</link><description>[at noodls] - Q3 2016 FINANCIAL RESULTS CONFERENCE CALL &amp; WEBCAST The text version of this document is not available at the moment. The original content was posted at original link . ProMetic Life Sciences Inc. published ...</description><guid isPermaLink="false">yahoo_finance/1779643547</guid><pubDate>Wed, 09 Nov 2016 20:51:05 GMT</pubDate></item><item><title>PROMETIC TO REPORT ITS THIRD QUARTER 2016 FINANCIAL RESULTS AND HOLD CONFERENCE CALL / WEBCAST</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283it2vq/*http://www.publicnow.com/view/5C24B80785DC6D7592C25C29887BE7E6C2E9D3C0</link><description>[at noodls] - LAVAL, QUEBEC, CANADA -November 9, 2016 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ('ProMetic' or the 'Corporation') announced today that it will report its financial results for the third ...</description><guid isPermaLink="false">yahoo_finance/1550550504</guid><pubDate>Wed, 09 Nov 2016 20:29:59 GMT</pubDate></item><item><title>PROMETIC ANNOUNCES CLOSING OF TELESTA THERAPEUTICS INC. ACQUISITION</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128t98uh8/*http://www.publicnow.com/view/DB9A4060199AA8A0A834F6CE8BBBF1AB2970DFE1</link><description>[at noodls] - Provides approximately $34 million in cash to be deployed towards drug development and clinical programs; Provides up to $50 million in potential tax attributes; Provides the opportunity for further integration ...</description><guid isPermaLink="false">yahoo_finance/853235236</guid><pubDate>Mon, 31 Oct 2016 13:43:08 GMT</pubDate></item><item><title>PROMETIC&#8217;S PLASMINOGEN MEETS PRIMARY AND SECONDARY END POINTS IN PIVOTAL PHASE 2/3 TRIAL</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1281k7vs2/*http://www.publicnow.com/view/E59AD0DDFFCE8128BDDEF144B6938A983B657C1D</link><description>[at noodls] - 100% success rate on meeting clinical trial's primary end points required for Accelerated Approval Regulatory Pathway 100% clinical response rate with healing of lesions within weeks of treatment Successful ...</description><guid isPermaLink="false">yahoo_finance/2149671106</guid><pubDate>Wed, 26 Oct 2016 10:55:04 GMT</pubDate></item><item><title>PROMETIC&#8217;S PBI-4050 MEETS PRIMARY AND SECONDARY END POINTS IN METABOLIC SYNDROME AND TYPE 2 DIABETES PHASE 2 CLINICAL TRIAL</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128lh9r03/*http://www.publicnow.com/view/98B51DB6B904DF076895212A638CA1B85156BE40</link><description>[at noodls] - Clinically and statistically significant reduction of glycated hemoglobin ('HbA1c') originally observed at 12 weeks is maintained at 24 weeks of treatment Clinically and statistically significant reduction ...</description><guid isPermaLink="false">yahoo_finance/2045409683</guid><pubDate>Thu, 20 Oct 2016 11:08:09 GMT</pubDate></item><item><title>PROMETIC&#8217;S PBI-4050 SIGNIFICANTLY REDUCES LIVER FIBROSIS IN PATIENTS WITH ALSTR&#214;M SYNDROME</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128mgumr0/*http://www.publicnow.com/view/FF746773DB4777DFB9F6E53D0D57705416DCB1B5</link><description>[at noodls] - Significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment Liver enzymes reduced to within normal ranges in all patients that completed ...</description><guid isPermaLink="false">yahoo_finance/2290509197</guid><pubDate>Wed, 12 Oct 2016 11:13:06 GMT</pubDate></item><item><title>PROMETIC ANNOUNCES THE ADDITION OF TYMPANIC MEMBRANE PERFORATIONS (TMPs) TO ITS PLASMINOGEN&#8217;S TARGETED INDICATIONS</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128c1p6oi/*http://www.publicnow.com/view/12D42A2E954F7DE85396BD8305DB5DCACA0DCEE0</link><description>[at noodls] - Over 100,000 surgeries performed annually in the USA alone for persistent tympanic perforations New Plasminogen formulation optimized for wound healing indications Global patent protection for this new ...</description><guid isPermaLink="false">yahoo_finance/2023242680</guid><pubDate>Tue, 06 Sep 2016 09:48:12 GMT</pubDate></item><item><title>PROMETIC ANNOUNCES AGREEMENT TO ACQUIRE TELESTA THERAPEUTICS INC. IN ALL SHARE TRANSACTION</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=12842v70l/*http://www.publicnow.com/view/774BD0844BD88BF187F2C3E82E78F8796FD9DBC9</link><description>[at noodls] - LAVAL, QUEBEC, CANADA - August 24, 2016 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ('ProMetic' or the 'Corporation') announced today that it has entered into a binding agreement (the 'Agreement') ...</description><guid isPermaLink="false">yahoo_finance/4175317087</guid><pubDate>Wed, 24 Aug 2016 10:18:11 GMT</pubDate></item><item><title>PROMETIC REPORTS SECOND QUARTER 2016 HIGHLIGHTS AND FINANCIAL RESULTS</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128683kng/*http://www.publicnow.com/view/2D3D1D992E52FB9300D5C861195781208DC2340E</link><description>[at noodls] - PBI-4050 clinical efficacy further evidenced in metabolic syndrome and type 2 diabetes patients Plasminogen FDA fast track designation secured, clinical efficacy further evidenced in plasminogen deficient ...</description><guid isPermaLink="false">yahoo_finance/873600222</guid><pubDate>Thu, 11 Aug 2016 21:11:06 GMT</pubDate></item><item><title>PROMETIC COMPLETES PATIENTS&#8217; ENROLMENT IN PIVOTAL PLASMINOGEN PHASE 2/3 CLINICAL TRIAL</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128ecn356/*http://www.publicnow.com/view/41B22CF380AF94FBBF26C8D953561AEA487A59C8</link><description>[at noodls] - Patients enrolment for the accelerated regulatory approval pathway completed Filing of Biologics License Application ('BLA') to start in Q4 2016 LAVAL, QUEBEC, CANADA - August 11, 2016 - ProMetic Life ...</description><guid isPermaLink="false">yahoo_finance/1045709275</guid><pubDate>Thu, 11 Aug 2016 12:01:22 GMT</pubDate></item><item><title>PROMETIC COMPLETES ADULT PATIENTS&#8217; ENROLMENT IN PIVOTAL IVIG PHASE 3 CLINICAL TRIAL</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=12828cm8u/*http://www.publicnow.com/view/73A068323D4D391951E95B3CECDCC601C49F0505</link><description>[at noodls] - Milestone achieved five months ahead of schedule ProMetic well positioned to become first Canadian provider of locally manufactured IVIG to serve rapidly growing Canadian market LAVAL, QUEBEC, CANADA - ...</description><guid isPermaLink="false">yahoo_finance/595413996</guid><pubDate>Tue, 09 Aug 2016 10:50:09 GMT</pubDate></item><item><title>PROMETIC&#8217;S PLASMINOGEN GRANTED FAST TRACK DESIGNATION BY THE US FDA</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1280v0olr/*http://www.publicnow.com/view/7F28D4006287F9B58853FAA0AB4864772FDB1490</link><description>[at noodls] - LAVAL, QUEBEC, CANADA - June 13, 2016 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ('ProMetic' or the 'Corporation') reported today that the U.S. Food and Drug Administration (FDA) has granted ...</description><guid isPermaLink="false">yahoo_finance/400961964</guid><pubDate>Mon, 13 Jun 2016 10:59:05 GMT</pubDate></item><item><title>PROMETIC TO PRESENT NEW DATA ON HOW PBI-4050 KEEPS PANCREATIC BETA CELLS ALIVE AT THE AMERICAN DIABETIC ASSOCIATION&#8217;S UPCOMING ANNUAL MEETING</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128ilgls4/*http://www.publicnow.com/view/862BA8491B1378053542ACBA7D33CD8C0013F66F</link><description>[at noodls] - PBI-4050's unique mechanism of action shown to keep insulin-producing pancreatic beta cells alive PBI-4050 reduces endoplasmic reticulum ('ER') stress and enables self-repair of the islets otherwise downregulated ...</description><guid isPermaLink="false">yahoo_finance/369900924</guid><pubDate>Thu, 09 Jun 2016 11:39:07 GMT</pubDate></item><item><title>PROMETIC ANNOUNCES CLOSING OF $60 MILLION BOUGHT DEAL OFFERING OF COMMON SHARES</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1285q3ejn/*http://www.publicnow.com/view/237D40FFE15CEC3D1CBA6FEBD8CFB556852EED38</link><description>[at noodls] - LAVAL, QUEBEC, CANADA - May 25, 2016 - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)('ProMetic' or the 'Corporation') closed today its previously announced bought deal public offering of common ...</description><guid isPermaLink="false">yahoo_finance/9906348</guid><pubDate>Wed, 25 May 2016 14:46:06 GMT</pubDate></item></channel></rss>